Atavistik Bio, a biotechnology company focused on developing transformative small molecule therapeutics with its AMPS platform, appointed Bryan Stuart as Chief Executive Officer and a director on the company’s board. Stuart will succeed Jeff Goater, a venture partner at The Column Group, who has served as interim CEO of Atavistik Bio since January 2022. Goater will continue to serve as a director on Atavistik Bio’s Board.

Stuart was most recently CEO of Fulcrum Therapeutics, where he initially served as chief operating officer. Prior to joining Fulcrum, he served as president and CEO of Yarra Therapeutics (a subsidiary of Array BioPharma) and CEO of Kastle Therapeutics, companies focused on developing therapies for rare and severe diseases. Previously, Stuart served as chief business officer of Civitas Therapeutics and also led business development, corporate development, and strategy at both EKR Therapeutics and Ovation Pharmaceuticals.

“We are delighted to welcome Bryan as CEO to steer the exciting growth ahead for Atavistik Bio,” said John Josey, Atavistik Bio’s board chair. “With Bryan’s proven track record stewarding candidates from the clinic to commercialization, we are confident he is the right person to lead Atavistik Bio into its next critical stage. We are extremely grateful to have had Jeff’s insightful leadership during the planned interim period and look forward to his continued contributions as a member of the Board.”

Stuart said, “I am extremely excited to join Atavistik Bio as CEO. Atavistik is poised to be a true disruptor in small molecule drug discovery with the tremendous progress and validation of the AMPS platform. AMPS has now demonstrated a reproducible ability to interrogate protein-metabolite interactions to unlock functional allosteric binding sites, and then engineer novel small molecules to elicit the desired therapeutic effect. This creates the opportunity for tremendous impact across many diseases. I look forward to working with the board and the exceptional Atavistik Bio team to continue the company’s mission of delivering transformative medicines to improve patients’ lives.”